Does 7-OH Actually Meet the Legal Standard for Emergency Scheduling?

NewsAdvocacy

Jul 7

A close reading of what 21 U.S.C. § 811(h) requires — and what the DEA's own record shows

NEWS ANALYSIS | July 7, 2026 | Kratom Truth Project‍ ‍

By Kratom Truth Project‍ ‍

_______________________________________

TL;DR

Emergency scheduling under 21 U.S.C. § 811(h) isn't a general referendum on whether 7-OH is good or bad. It has one legal trigger: the DEA must find that a Schedule I placement is necessary to avoid an imminent hazard to public safety. This piece reads that standard and applies it to the record the DEA actually assembled.

What the DEA counts as a "7-OH death" isn't what it sounds like. The agency points to cases it codes as single-substance — 7-OH alone — to argue the drug is killing people on its own. But those cases rest on what the person said they took, not on testing the actual product. Nothing was assayed; nothing was screened for adulterants — in a market where products sold as "7-OH" have been found laced with tianeptine, and where the notice itself admits these products come from unknown sources with "identity, purity, and quantity ... uncertain and inconsistent." You cannot call a death a confirmed single-substance 7-OH death when you never confirmed what was in the bottle. There are no confirmed single-substance deaths attributable to 7-OH — and the DEA's own words about product purity are what give that away.
The Schedule I abuse finding rests on an intravenous study of an oral product. The reinforcement evidence traces substantially to a single rat study using intravenous self-administration — which bypasses the nausea ceiling that limits real oral kratom dosing — with no controlled human clinical trials. That same study found the plant's primary alkaloid, mitragynine, was not self-administered at any dose. The most dramatic case the notice cites — a self-amputation — comes from a paper whose own title names cannabis as a co-cause. And the "rapid escalation" in poison-center data tracks the moment dedicated tracking codes were switched on in 2025, not a demonstrated rise in incidence.
But even taken at face value, the record doesn't meet the standard. The fatal cases the DEA cites often also contained fentanyl, benzodiazepines, and ketamine — substances independently lethal at ordinary doses. The methodology can't isolate 7-OH's contribution, and the notice doesn't claim to. Presence isn't causation.
The numbers have no denominator. Read against a user base in the millions across tens of thousands of retail locations, the cited figures describe an extraordinarily low event rate — well below substances sold freely in grocery stores. Acetaminophen alone accounts for far more harm and isn't being emergency-scheduled.
The "abuse" the factors require isn't what the record shows. Much of it is therapeutic dependence and pain/recovery management — a real but legally different category from abuse as the statute defines it.
The strongest argument isn't about the science at all. A § 811(h) order can impose a two-year Schedule I ban, is not subject to judicial review, and the DEA's position is that ordinary APA comment protections don't even apply. The only real check is the comment record — which is exactly why commenting matters.

The comment period (docket HHS-OASH-2026-0232) closes July 31, 2026. A comment doesn't have to win in court — it builds the record. → kratomtruthproject.org/comment-on-7-oh

_______________________________________

Almost every argument in the 7-OH scheduling fight is being fought on the science. Is it dangerous? Is it an opioid? How many people has it hurt? Those questions matter, but they are not the question the law actually asks. Emergency scheduling has its own legal test, written into the statute, and the DEA has to meet that test — not win a general argument about whether 7-OH is good or bad.

This piece does something almost nobody in this debate has done: it reads the actual standard, applies it to the record the DEA actually assembled in its July 2026 notice, and asks a narrow question. Not "is 7-OH safe?" — but "has the agency met the specific legal burden the statute sets for taking a substance off the market by emergency order?"

The answer is more interesting than either side's slogans. The DEA's record contains real data that has to be engaged, not dismissed. And the legal case against this action is stronger than the action's confident framing implies — but for reasons that have almost nothing to do with the body count, and almost everything to do with a process that was built to be nearly impossible to challenge.

1. What the statute actually requires

Temporary — or "emergency" — scheduling lives in 21 U.S.C. § 811(h). It is a deliberately lower bar than permanent scheduling, and it was designed to be fast. But it is not no bar.

To place a substance temporarily in Schedule I, the Attorney General (acting through the DEA) must find that doing so is "necessary to avoid an imminent hazard to public safety." That phrase is the entire legal trigger. Not "a hazard." Not "a potential future risk." An imminent hazard.

In making that finding, the statute directs the agency to consider three of the eight factors used for permanent scheduling — specifically factors (4), (5), and (6) of § 811(c):

(4) the drug's history and current pattern of abuse
(5) the scope, duration, and significance of abuse
(6) what, if any, risk there is to the public health

That's it. Those three factors, in service of one finding: imminent hazard.

Now the three structural facts that matter more than any of the science — all of them drawn straight from the DEA's own notice:

A temporary order can last two years. Under § 811(h), the DEA can place a substance in Schedule I on a temporary basis for up to two years without a public hearing, provided HHS does not object — and it can be extended for up to a third year. That is not a brief holding pattern. It is a multi-year prohibition imposed before any of the ordinary permanent-scheduling analysis is complete.

It is not subject to judicial review. This is stated in the statute and repeated in the notice: a temporary scheduling order issued under § 811(h) is not subject to judicial review. You cannot take it to court to test whether the "imminent hazard" finding was supported. That door is closed by design.

The DEA takes the position that ordinary notice-and-comment rules don't apply. Because § 811(h) directs the agency to act by order rather than by rulemaking, the DEA's position is that the Administrative Procedure Act's notice-and-comment requirements do not govern this notice of intent.

Hold those three facts in your head, because they reframe everything that follows. A two-year Schedule I placement, insulated from judicial review, issued through a process the agency says the APA's comment protections don't reach. That is the actual structure of what is happening. The imminent-hazard finding is the only real check — and it is a check the agency largely grades itself on.

2. What "imminent hazard" was built to mean

The emergency-scheduling power was created for a specific problem: novel synthetic drugs appearing on the street and causing an acute, rising wave of harm faster than the normal scheduling process could respond. The synthetic-cannabinoid and novel-opioid waves are the textbook cases — a substance nobody had heard of eighteen months earlier, suddenly filling emergency rooms.

The word doing the work is imminent. The power exists to stop a fire that is actively spreading, not to resolve a long-running policy debate about a substance that has been sold openly in tens of thousands of retail locations for years. That distinction is not rhetorical. It is the difference between the tool the statute created and the use it is being put to.

So the honest question is: does the DEA's record describe an acute, rising, novel emergency — or does it describe a substance the agency has decided it wants gone, using the fastest available mechanism?

3. The three factors, applied to the DEA's actual record

Here is where intellectual honesty matters, because the record in the July 2026 notice contains real single-substance data — not only polydrug cases. Any comment that pretends otherwise gets rebutted by the DEA in a single line.

What the notice actually cites:

DEA TOX identified 7-OH in 85 cases since 2019, of which 55 were fatal.
FAERS (the FDA's adverse-event system) shows 9 deaths, with 79 of 86 cases reported as serious.
Poison-center data, January–July 2025, shows 165 exposure cases. Among those exposed to 7-OH alone, roughly 35% resulted in serious medical outcomes and 67% were treated at a healthcare facility.
Individual single-substance case reports, including a naloxone-reversed cardiopulmonary arrest and an inpatient buprenorphine-managed detox.

This is a real record. It is not nothing, and an honest reading does not pretend it is nothing. But it is essential to be precise about what the record actually establishes — because the agency's framing claims more than its methodology can support.

The critical distinction is "single-substance as reported" versus "single-substance as verified." The poison-center cases coded as "7-OH only" and the individual case reports rest on consumer self-report and intake history — what the person said they took. They do not rest on product testing. In these cases the product was not seized and assayed, the actual 7-OH content was not confirmed, and the sample was not screened for adulterants. That gap is decisive in this market, because products marketed as "7-OH" or "kratom extract" have documented contamination with tianeptine and other adulterants. And this is not a point the agency can dispute — the notice itself states that these products are obtained through unknown sources and that their "identity, purity, and quantity ... are uncertain and inconsistent." That admission is fatal to the single-substance characterization: the agency cannot simultaneously concede it cannot verify the identity, purity, or quantity of what is in these products and code the resulting cases as clean "7-OH only" exposures. A case coded "7-OH only" based on what a consumer reported buying — from a product the DEA itself admits is of uncertain identity and composition, in a documented contamination environment — is not clinical confirmation that 7-OH caused the outcome. It is an association derived from an unverified label.

So the precise picture is this: there are no confirmed single-substance deaths attributable to 7-OH. "Confirmed" is the operative word. The record contains cases reported as single-substance, but reporting is not confirmation, and the methodology contains no step — no product assay, no adulterant screen — that could turn one into the other. It is worth being exact about what this does and doesn't mean. It does not mean there is no evidence of harm from 7-OH in isolation — the agency can point to its self-reported single-substance cases, and it would. What it means is narrower and sturdier: none of those cases is confirmed, because the agency cannot point to the product testing that would confirm them. The distinction is the whole ballgame, and it runs on the DEA's own admission about product purity.

So what else can be said about this record, honestly?

First — presence is not causation, and the factors ask about causation. DEA TOX finding 7-OH "in" 85 cases means it was detected, not that it was the cause. Adverse-event and post-mortem toxicology databases are designed to capture association — they are explicitly not designed to establish that the detected substance caused the outcome. The statutory factors (4)–(6) ask about the drug's actual contribution to abuse and public-health risk; detection in a decedent does not, by itself, answer that.

The notice's own language makes this concrete. The DEA acknowledges that the fatal cases it cites often contained other drug classes — opioids such as fentanyl, benzodiazepines such as bromazolam, and ketamine. That is the record disqualifying itself. Fentanyl is independently lethal at microgram doses; benzodiazepine-opioid combinations are a well-characterized cause of fatal respiratory depression. These are not incidental co-factors — they are substances with documented independent lethal potential at ordinary doses. In a case where 7-OH is detected alongside fentanyl and a benzodiazepine, the methodology simply does not permit isolating 7-OH's contribution to the death — and the notice does not claim to. It counts the case anyway.

FAERS specifically is a weaker foundation than the raw count suggests. FAERS is a passive surveillance system — voluntary, self-reported, accepting of duplicate entries, and explicitly built to capture association rather than causation. For 7-OH, one problem compounds all the others: contamination. Products marketed as "7-OH" or "kratom extract" have been found to contain tianeptine — a substance with severe opioid-like dependence properties that adverse-event databases don't track separately. There is no way to determine from the current record how many events attributed to 7-OH involved a product that was actually adulterated with something else. The agency's record doesn't control for this, which means the FAERS figures may be logging tianeptine harms as 7-OH harms. That is not a minor caveat about database hygiene — it is a fundamental question mark over the evidentiary foundation of factor (6).

Second — the denominator is missing, and it is enormous. A number like "165 exposure cases over seven months" or "55 fatalities since 2019" has to be read against the size of the exposed population. 7-OH products have been sold across a national market of tens of thousands of retail locations. Against a user base plausibly in the millions, these figures describe an extraordinarily low event rate — orders of magnitude below substances that remain unscheduled and sold in grocery stores. A raw count with no denominator is the single most common way risk gets made to look larger than it is. The notice supplies the numerator and is silent on the denominator.

For scale: acetaminophen sends an estimated 50,000-plus Americans to emergency rooms each year and is involved in hundreds of deaths annually, sold in effectively unlimited quantities with no age restriction. No one is convening an emergency-scheduling action on acetaminophen. The comparison is not an argument that 7-OH is safe — it is an argument that the magnitude of the cited numbers, read against any realistic denominator, is not the signature of an imminent public-safety emergency.

And the "rapid escalation" is partly a measurement artifact. The notice leans on a sharp rise in poison-center exposures as evidence of a growing emergency. But it also states plainly that reporting for 7-OH was "historically limited within the National Poison Data System (NPDS)" and that dedicated data codes for the substance were implemented "between February and May 2025." The escalation the notice then describes is measured across exactly that window and forward. A rise measured from a period when the substance had no dedicated tracking code to a period after the code existed is, in significant part, measuring when the system started counting — not a real change in incidence. You cannot tally what you have no code for; add the code, and recorded cases rise regardless of whether underlying behavior changed at all. An escalation curve that begins the moment the measurement instrument is switched on is the textbook definition of a surveillance artifact, and it cannot by itself carry an "imminent, accelerating hazard" finding without controlling for the coding change.

Third — the hard cases have to be met, not dodged. The notice contains at least one genuinely grim case reported as single-substance (a 2025 psychosis case involving self-injury). A serious analysis does not flinch from that. But look closely at what the agency is doing with it. The self-amputation case the notice cites is drawn from a paper whose own title names cannabis as a co-involved substance — Broul et al. (2025), Case Report: Cannabis and kratom-induced self-amputation of ears and penis (notice footnote 41). This matters beyond mere co-presence: cannabis-induced psychosis is a recognized clinical entity in the DSM-5, specifically associated with high-potency THC and supported by a substantial peer-reviewed literature. So the most dramatic single case in the entire notice — the one that does the most rhetorical work — involves a named co-substance that has its own well-characterized pathway to precisely the outcome observed, and the notice's characterization omits it. Attributing the psychosis to 7-OH alone, when the agency's own cited source names a co-factor with a documented mechanism for that exact result, is not supported by the paper the DEA chose to rely on. Beyond that, the case carries the same limitation as every other "single-substance" case here — the product was not tested or screened for adulterants, so "7-OH only" reflects intake history, not verified exposure.

Set that aside and the deeper point still holds. The legal question is not "can any severe individual case be found" — for virtually any substance in wide use, including many sold freely, the answer is yes. The question the statute asks is whether the pattern rises to an imminent hazard. One or several severe case reports, however disturbing, are what you would expect to find in the safety literature of almost any widely used compound. They establish that harm is possible. They do not establish that it is imminent and widespread in the way the emergency power requires.

The through-line: even taking the DEA's stronger-than-expected record entirely at face value, what it describes is a low-event-rate substance with real but sparse associated harms and a missing denominator — not the acute, spreading, novel emergency that "imminent hazard" was written for.

4. The word "abuse" is doing more work than the record supports

Factors (4) and (5) are about abuse — its pattern, scope, and significance. And here the analysis exposes something the notice glides past: "abuse" has a legal meaning, and most of what the record documents isn't it.

Abuse, in the scheduling context, has a specific meaning: non-medical, non-supervised use for psychic effect, with associated dysfunction or harm. Factor (4) asks about the "history and current pattern of abuse" — not dependence, not therapeutic use without a prescription, not recreational use broadly defined. Abuse potential, as developed in scheduling law and pharmacology, turns on reinforcing properties, escalation, compulsive drug-seeking, and diversion — the behavioral signature of addiction. It is not satisfied by two things the record leans on heavily:

Receptor activity is not abuse. That 7-OH is active at opioid receptors tells you its mechanism, not that it is abused. Loperamide (Imodium) is an opioid-receptor agonist sold in every grocery store. Endogenous endorphins hit the same receptors. Mechanism is not behavior.

Adverse events are not abuse. A serious medical outcome tells you something happened; it does not tell you it happened through the pathway of compulsive, escalating, drug-seeking use that "abuse potential" actually denotes.

This matters because the record blurs three genuinely different things:

Abuse — compulsive, reinforcing, escalating use; the legal target.
Dependence — physiological adaptation that produces withdrawal on cessation. This is a property of many legitimate, prescribed medications. Antidepressants, beta-blockers, and countless others produce dependence in the clinical sense. Dependence is not abuse, and the law knows the difference.
Therapeutic reliance — a person using a substance consistently because it manages a real condition (pain, opioid-use-disorder self-management), the same way millions rely on prescribed medication daily.

When the notice points to "dependence" or to people using 7-OH regularly, it is very often describing the second and third categories, not the first — and then folding them into the language of "abuse" to satisfy factors (4) and (5). A person who takes 7-OH every day to manage chronic pain is, on this record, indistinguishable from a patient who takes a prescribed medication every day for the same reason. The statute's "abuse" factors were not written to capture that person. The record does not do the work of separating the person it was written to capture from the far larger group it was not.

And the affirmative abuse-potential finding rests on remarkably thin — and misapplied — evidence. The Schedule I designation requires a high potential for abuse, the most serious of the three tiers. Yet the preclinical reinforcement evidence for 7-OH traces substantially to a single study — Hemby SE et al., Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine, Addiction Biology 24(5):874–885 (2019) — conducted in rats, with no controlled human clinical trials of 7-OH's abuse liability in the literature. That alone is a striking evidentiary posture: the strictest schedule in federal law, resting substantially on one animal study, with no human clinical trial data on the question.

But the deeper problem is what that study actually was, and what it found. Hemby used an intravenous self-administration paradigm in rats — the standard laboratory model for drugs delivered directly into the bloodstream, not for an orally consumed botanical. Two facts the agency's summary passes over:

The same study found that mitragynine — the primary kratom alkaloid, the dominant component of the plant's alkaloid content — was not self-administered at any dose tested. In the paper's own words, 7-HMG but not MG substituted for morphine, and rats did not acquire self-administration of mitragynine at any of the doses tested. The agency's own cited source cuts directly against the broader "kratom is dangerously reinforcing" narrative even as it is deployed to support scheduling.
The intravenous route bypasses the oral nausea ceiling. Kratom's real-world dose is self-limiting: oral consumption produces nausea and vomiting past a certain point, a natural biological brake well documented in actual use. An intravenous model categorically bypasses that brake. At the doses that produce self-administration by direct IV delivery, an oral consumer would be vomiting long before reaching comparable plasma concentrations. The abuse potential the study demonstrates exists in a pharmacological context — direct intravenous infusion, no nausea ceiling — that cannot occur through oral kratom use. Using it to characterize the abuse potential of an oral botanical is a route-of-administration category error.

So the "high potential for abuse" finding rests on an intravenous study, applied to an oral product, whose own data on the primary alkaloid points the other way. A finding of that magnitude built on that base is precisely what a factor-by-factor challenge exists to test. (The injection-route problem and the impossible-dose math are documented study-by-study in KTP's The 7-OH Science Fraud.)

Factor (5) leans partly on social-media monitoring. For the "scope and significance of abuse" factor, the notice draws on web monitoring of Reddit discussions — it states that "the National Drug Early Warning System (NDEWS) conducted web monitoring on reddit mentions of kratom and its deriva[tives]," and reports what "reddit discussants" said about redosing, euphoria, and product comparisons. Whatever value anecdotal online discussion has as a signal, it is not validated epidemiological data — it is unverified, self-selected social-media posting, with no denominator, no clinical confirmation, and no control for the contamination problem discussed above. Citing it as evidence of the scope of abuse is a category error: it measures conversation, not incidence.

Worse, forums of this kind are demonstrably manipulable, which makes them uniquely unsuited to bear evidentiary weight. Analysis of the specific communities that feed this kind of monitoring has found a large share of the most dramatic posts coming from accounts active in only that one forum, alongside heavily templated language patterns — the signature of coordinated posting rather than organic reporting. A data source that can be seeded and amplified is not a measure of real-world incidence; it is a measure of who is posting. When an agency elevates that into a scheduling factor, it imports whatever manipulation is present in the source directly into the federal record. (KTP has documented these patterns in detail — see The Influencer Propaganda Machine.)

5. The consistency problem: the same yardstick, applied honestly

If factors (4)–(6) are applied to 7-OH and produce "imminent hazard," intellectual honesty requires asking what the same factors produce when applied to substances that remain unscheduled and freely sold. This is not whataboutism — it is the core of an arbitrary-and-capricious analysis. A standard applied to one substance and not to materially more dangerous ones is, as a matter of administrative law, evidence that the standard is not being applied as an objective test.

Measured by the statute's own factors:

Alcohol — unambiguous abuse potential, well-characterized dependence, a defined lethal dose, withdrawal that can itself be fatal, and a death toll in the range of 178,000 per year in the United States. Unscheduled. Sold in grocery stores.
Prescription opioids and benzodiazepines — higher intrinsic abuse potential than 7-OH, Schedule II and IV, still prescribed and diverted at scale. Notably, these are frequently the very drugs 7-OH users report leaving. If abuse potential were the operative driver, the comparison runs the wrong way for the agency.
Loperamide (Imodium) — a genuine opioid with documented high-dose abuse and cardiac deaths, completely over-the-counter.
Dextromethorphan (DXM) — real abuse potential, over-the-counter.

Apply factors (4)–(6) honestly and several of these clear the "abuse and public-health risk" bar more convincingly than 7-OH does — and none is being emergency-scheduled. The point is not "therefore ban alcohol." The point is narrower and sharper: a factor test that captures 7-OH but not these is not functioning as an objective measure of hazard. It is functioning as a selection. That is the definition of arbitrary and capricious.

The comparison deliberately stays inside the controlled-substances universe. Sugar, junk food, and the broader "everything carries some risk" point are a different kind of argument — they don't bear on how the Controlled Substances Act's factors are applied, because those things were never candidates for scheduling in the first place. Alcohol, opioids, benzodiazepines, and OTC opioids are the comparisons that matter here, because they live in the same regulatory world the statute governs and are measured by the same factors.

6. The threshold, the "synthetic" framing, and what they reveal

The proposed action turns on a 0.05% threshold — products above that concentration of 7-OH fall under the order. Two things about that number deserve scrutiny.

It captures botanical material by design. 7-OH occurs naturally in the kratom leaf. A concentration line drawn low enough sweeps in far more than concentrated isolates. The threshold is not a neutral safety line; it is a market-definition line, and where it is drawn determines who is in business and who is not.

The "synthetic" framing collapses on its own logic. The action leans on characterizing concentrated 7-OH as a "synthetic" or "semi-synthetic" opioid to heighten its threat profile. But as KTP has documented at length, if 7-OH were genuinely a novel synthetic compound, there would be a patent trail — novel synthetic molecules are patented, because that is the entire commercial point of synthesizing them. The absence of that trail for the "synthetic opioid" being described is telling. You cannot simultaneously argue that a substance is a dangerous novel synthetic worthy of emergency action and that it is the same naturally occurring metabolite the body already produces when it processes the plant. The framing wants both and can have neither.

A threshold set to capture botanical material, justified by a "synthetic" characterization that doesn't survive the patent question, is not the fingerprint of a public-safety emergency. It is the fingerprint of market structuring — clearing a field.

7. Follow the incentives (carefully)

Here the analysis has to be disciplined, because there is a strong version of the "real motive" question and a weak one, and the difference matters.

The weak version asserts, as established fact, that the DEA is acting because pharmaceutical interests directed it to. That cannot be sourced. Intent you cannot prove is not evidence — it is speculation, and it does not belong in an analysis that means to be taken seriously.

The strong version stays on documented pattern and structural incentive, and it is genuinely damning without needing a smoking gun:

7-OH is being actively pursued as a patentable pharmaceutical asset. Isolated, standardized, or slightly modified forms of a naturally occurring compound are the raw material of drug development.
A regulatory line that removes the accessible botanical-derived version from the market clears the field for a future patented isolate to enter it — as a controlled, prescribed, monetized product. The public loses cheap access; a patent holder gains a market with the competition already removed by federal action.
This is not a novel or conspiratorial dynamic. It is the documented pattern of drug policy — the same arc by which a freely available botanical becomes, through scheduling and reformulation, a patented prescription product. KTP has traced this playbook across the cannabis-to-Marinol history and the state-level legislative campaigns.

The honest framing is "who benefits, and what is the documented pattern" — not "here is proof of a directed scheme." Follow the incentives, name the beneficiary, show the precedent. That framing holds precisely because it does not overclaim: it asks the reader to weigh a structure of incentives and a documented history, not to accept an accusation on faith.

And this is where the structural facts from Section 1 stop being background and become the point.

8. The honest caveat — which in this case is the whole argument

Every serious legal-analysis piece owes its reader a caveat about how hard the argument is to win. In most administrative fights, that caveat is a note of humility. Here, the caveat is the indictment.

The DEA receives substantial deference on imminent-hazard findings. Temporary scheduling orders are, by the statute's own terms, not subject to judicial review. The agency's position is that APA notice-and-comment protections do not apply — a position that is itself disputed among administrative-law scholars, since the practical substance of a two-year federal prohibition does not become less significant because it arrives by order rather than by rulemaking. Put those together and the picture is stark: a two-year Schedule I prohibition can be imposed on the basis of a self-graded "imminent hazard" finding, built on an associational record with no denominator, with no court able to test whether the finding was supported, through a process the agency says the ordinary comment safeguards don't govern.

There is a further wrinkle that cuts against the agency on its own terms. The notice invokes the "good cause" exception under 5 U.S.C. 553(b)(B) to bypass notice-and-comment, asserting that further delay would be "impracticable and contrary to the public interest given the manifest urgency to avoid an imminent hazard to public safety." But the good-cause exception is reserved for genuine, acute emergencies — the situations where the time it takes to run a comment period would itself create immediate danger. It is a poor fit for a substance that has been sold openly across tens of thousands of retail locations for years. The agency cannot easily explain why a hazard it characterizes as long-developing and market-wide suddenly requires bypassing the public-comment protections that would ordinarily apply — asserting good cause here tests the concept well beyond its intended application. The urgency required to justify skipping process is in tension with the timeline the record itself describes.

The strongest argument against this action, in other words, is not that the science is wrong. It is that the process is structurally insulated from the checks that are supposed to catch exactly this — a low-event-rate substance swept up by an emergency power built for acute crises, justified by "abuse" language the record doesn't support, behind a threshold that reads as market design, with a beneficiary the incentives point to and a courthouse door that is locked.

That is not a courtroom prediction. It is the observation that when a power is this insulated from review, the only remaining check is the public record built during the comment window — which is precisely why the comment window matters even though the agency says the APA doesn't require it.

ACTION REQUIRED

Submit Your Public Comment Before July 31

HHS Docket HHS-OASH-2026-0232 is open. KTP built a free generator that writes your personalized comment in under 2 minutes — no form letter, no account required.

Generate Your Comment → Closes July 31

9. What this means for your comment

The formal comment period on the 7-OH notice (docket HHS-OASH-2026-0232) closes July 31, 2026. Because a temporary order is not judicially reviewable, the comment record is the primary place this action can be contested at all. A comment does not have to win in court — it has to build the record.

The comments that carry weight on this record are the ones that engage the legal standard directly rather than only arguing the science:

State the actual test — § 811(h)'s "imminent hazard" finding and factors (4)–(6) — and argue the record doesn't meet it.
Attack causation vs. presence and the missing denominator, rather than denying harm exists.
Make the precise single-substance point: the "7-OH only" cases rest on self-report from untested products the notice itself concedes come from unknown sources, with identity, purity, and quantity "uncertain and inconsistent" — so no death is a confirmed single-substance 7-OH death.
Note the thinness of the abuse-potential finding — a Schedule I "high potential for abuse" designation resting on a single animal study with no human clinical trials — and that factor (5) leans on Reddit monitoring, which is commentary, not epidemiology.
Point out the surveillance artifact: the "escalation" tracks the 2025 rollout of dedicated tracking codes, not a real rise in incidence.
Name the good-cause problem: the emergency justification for skipping notice-and-comment doesn't fit a product openly sold for years.
Draw the abuse / dependence / therapeutic-reliance distinction the record blurs.
Raise the consistency problem with substances measured by the same factors and left unscheduled.
Name the non-reviewability and process concern directly — a two-year placement insulated from court review is itself a reason for the agency to proceed with extraordinary care and a fully supported record.

KTP's federal comment generator builds exactly these arguments into a submission in your own words. It now includes a policy point specifically on the legal-standard argument laid out here.

→ Comment on the 7-OH scheduling notice:kratomtruthproject.org/comment-on-7-oh